Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 96 Präparate · 6744 Quellenpassagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-089343 · Präparat HOS-083831
6
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): potassium (HOS-086929) amphotericin (HOS-088524) carbenoxolone (HOS-089156) penicillin G sodium (HOS-089157) heparin sodium (HOS-089158) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 51310a74f30b964c7791524bf84074d7bc087b7392957520e24cde77e6580a84 · Zeichen 1715–2596 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 22–23
HOS-089377 · Präparat HOS-083831
22
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): potassium (HOS-086929) amphotericin (HOS-088524) carbenoxolone (HOS-089156) penicillin G sodium (HOS-089157) heparin sodium (HOS-089158) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 3841af3357a6b556ffbe1ba585eac1e7bf20f0fc3570e5e588213cc0c4b3a13b · Zeichen 1717–2599 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 38–39
HOS-089412 · Präparat HOS-083831
38
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): potassium (HOS-086929) amphotericin (HOS-088524) carbenoxolone (HOS-089156) penicillin G sodium (HOS-089157) heparin sodium (HOS-089158) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 23798f26c1d10735ac1103845757c251001803747d2fddf0cb05a19068a26188 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 55–56
HOS-089447 · Präparat HOS-083831
55
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): potassium (HOS-086929) amphotericin (HOS-088524) carbenoxolone (HOS-089156) penicillin G sodium (HOS-089157) heparin sodium (HOS-089158) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage a26fad67a2ec8cdcb1ecacd438a628b3c48bc16decbc4fe714b306da0e88a2b6 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 72–73
HOS-089482 · Präparat HOS-083831
72
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): potassium (HOS-086929) amphotericin (HOS-088524) carbenoxolone (HOS-089156) penicillin G sodium (HOS-089157) heparin sodium (HOS-089158) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage c2b7f360d8b561f093a743dca5f3f4c2e65c52ad578491d1b450764778643626 · Zeichen 1716–2598 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.